This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Jennifer Lachey Biography and Net Worth

Insider of Keros Therapeutics

Jennifer Lachey has served as our Chief Scientific Officer since June 2019, and was previously our Vice President of Biology and Pharmacology beginning in July 2016. Prior to joining Keros, Dr. Lachey served as a Senior Director at Seres Therapeutics and was a Senior Director of Preclinical Pharmacology at Ember Therapeutics. Previously, Dr. Lachey was Associate Director of Preclinical Pharmacology at Acceleron Pharma. Dr. Lachey received a B.Sc. in Biology from Indiana University, and a Ph.D. in Neurobiology from the University of Cincinnati. Dr. Lachey completed her post-doctoral training at Beth Israel Deaconess Medical Center.

What is Jennifer Lachey's net worth?: The estimated net worth of Jennifer Lachey is at least $5.38 million as of July 15th, 2022. Dr. Lachey owns 95,100 shares of Keros Therapeutics stock worth more than $5,384,562 as of November 16th. This net worth approximation does not reflect any other investments that Dr. Lachey may own. Learn More about Jennifer Lachey's net worth.
How do I contact Jennifer Lachey?: The corporate mailing address for Dr. Lachey and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Jennifer Lachey's contact information.
Has Jennifer Lachey been buying or selling shares of Keros Therapeutics?: Jennifer Lachey has not been actively trading shares of Keros Therapeutics during the last ninety days. Most recently, Jennifer Lachey sold 46,034 shares of the business's stock in a transaction on Friday, July 15th. The shares were sold at an average price of $30.00, for a transaction totalling $1,381,020.00. Following the completion of the sale, the insider now directly owns 95,100 shares of the company's stock, valued at $2,853,000. Learn More on Jennifer Lachey's trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Julius Knowles (Director), and Jennifer Lachey (Insider). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, insiders at the sold shares 1 times. They sold a total of 250,000 shares worth more than $11,002,500.00. The most recent insider tranaction occured on August, 13th when Director Carl L Gordon sold 250,000 shares worth more than $11,002,500.00. Insiders at Keros Therapeutics own 22.9% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 8/13/2024.

Jennifer Lachey Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2022	Sell	46,034	$30.00	$1,381,020.00	95,100
7/13/2022	Sell	1,916	$30.00	$57,480.00	95,100
5/11/2022	Sell	5,300	$41.90	$222,070.00	85,700
4/11/2022	Sell	5,300	$62.77	$332,681.00	85,700
4/4/2022	Sell	7,950	$60.00	$477,000.00	85,700
3/11/2022	Sell	2,650	$53.38	$141,457.00
2/11/2022	Sell	2,650	$52.06	$137,959.00
1/11/2022	Sell	2,650	$53.75	$142,437.50
1/5/2022	Sell	2,650	$60.00	$159,000.00
12/15/2021	Sell	735	$50.00	$36,750.00
12/13/2021	Sell	1,915	$50.55	$96,803.25
11/10/2021	Sell	15,900	$60.00	$954,000.00
6/11/2021	Sell	2,650	$50.98	$135,097.00	1,000

Jennifer Lachey Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $56.62

$55.26

$60.58

50 Day Range

MA: $59.41

$53.88

$68.15

2 Week Range

Now: $56.62

$27.31

$73.00

Volume

526,789 shs

Average Volume

373,276 shs

Market Capitalization

$2.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad